Knowledge-based planning for stereotactic radiotherapy of peripheral early-stage lung cancer

Figures & data

Figure 1. Dosimetric results per patient. Patients 1–10 are 5 × 11 Gy cases while 11–20 are 3 × 18 Gy.

Figure 2. Dosimetric results per patient.

Table 1. Averaged RapidPlan results for 5 × 11 Gy patients of EG using Model_5 × 11 and Model_COMBI compared with respective clinical plans and clinical plans re-optimized using P013 [Clinical(PO)].

	Evaluation group (EG)
	5 × 11 Gy patients
	Clinical	Clinical (PO)	Model5 × 11	ModelCOMBI
Volume receiving × Gy
(%)
C. lung V5	0.8 ± 1.1	1.2 ± 1.3	1.6 ± 2.0	1.6 ± 1.9
Total lung – PTV V5	12.7 ± 3.3	12.8 ± 3.2	12.6 ± 3.2	12.5 ± 3.2
Total lung – PTV V20	4.0 ± 2.0	4.1 ± 2.0	3.8 ± 1.9	3.8 ± 1.9
(cm^3)
Thoracic wall V30	28.9 ± 14.9	25.4 ± 14.0^c	22.8 ± 14.1^c	22.3 ± 12.3^a^,^c
Thoracic wall V40	8.2 ± 5.7	7.7 ± 5.4	7.5 ± 5.5	8.4 ± 5.9
Thoracic wall V50	1.5 ± 1.2	1.7 ± 1.5	1.7 ± 1.4	1.9 ± 1.5
Mean dose (Gy)
ITV	67.6 ± 1.9	66.6 ± 2.2	67.7 ± 2.9	67.5 ± 2.4
PTV out OAR	63.6 ± 1.4	63.0 ± 1.8	63.5 ± 1.2	63.4 ± 0.9
PTV in OAR	56.8 ± 1.1	56.8 ± 1.5	57.1 ± 0.7	57.4 ± 1.0
C. lung	0.8 ± 0.3	0.9 ± 0.3	0.9 ± 0.3	0.9 ± 0.3
Total lung – PTV	2.9 ± 0.9	2.9 ± 0.9	2.8 ± 0.9^c	2.8 ± 0.8^c
Ring	32.1 ± 2.3	32.3 ± 2.1	30.6 ± 2.2	30.5 ± 2.3
Max dose (Gy)
PTV in OAR	62.1 ± 1.7	61.9 ± 1.7	63.2 ± 1.7	63.4 ± 2.0^a
Thoracic wall	54.7 ± 7.0	55.6 ± 7.9	54.3 ± 8.7	56.3 ± 7.3^b
Spinal cord	8.0 ± 4.3	8.2 ± 4.0	7.6 ± 2.2	8.3 ± 3.5
Esophagus	8.3 ± 4.0	9.4 ± 4.2^c	10.6 ± 5.1^c	10.7 ± 5.0^c
Trachea	6.8 ± 6.4	8.1 ± 6.9^c	8.6 ± 7.1	8.0 ± 6.5
Monitor units	2898 ± 497	2754 ± 335	2976 ± 452	2942 ± 452

C. lung: Contralateral lung; V_X: volume receiving × Gy.

^a Indicates a statistically significant difference (p < 0.05) between Model_{5 × 11/COMBI} and Clinical(PO);

^b Indicates a statistically significant difference (p < 0.05) between Model_COMBI and Model_5 × 11;

^c Indicates a statistically significant difference (p < 0.05) between Clinical and Clinical(PO) or Model_{5 × 11/COMBI}.

Table 2. Averaged RapidPlan results for 3 × 18 Gy patients of EG using Model_3 × 18 and Model_COMBI compared with respective clinical plans and clinical plans re-optimized using P013 [Clinical(PO)].

	Evaluation group (EG)
	3 × 18 Gy patients
	Clinical	Clinical (PO)	Model3 × 18	ModelCOMBI
Volume receiving × Gy
(%)
C. lung V5	0.1 ± 0.2	0.3 ± 0.4	0.1 ± 0.2	0.3 ± 0.3
Total lung – PTV V5	11.0 ± 3.1	11.0 ± 3.1	10.7 ± 3.2^a	10.7 ± 3.3
Total lung – PTV V20	2.3 ± 1.2	2.3 ± 1.1	2.0 ± 1.0^a^,^c	2.0 ± 1.0^a^,^b,^c
(cm^3)
Thoracic wall V30	5.8 ± 4.3	6.1 ± 4.5	6.8 ± 5.5	6.0 ± 4.6
Thoracic wall V40	1.3 ± 1.3	1.6 ± 1.6	1.8 ± 2.0	1.6 ± 1.8
Thoracic wall V50	0.1 ± 0.2	0.3 ± 0.4	0.4 ± 0.5	0.3 ± 0.5
Mean dose (Gy)
ITV	67.2 ± 3.0	66.7 ± 3.0	69.9 ± 3.3^a^,^c	69.3 ± 3.5^a^,^b,^c
PTV out OAR	61.8 ± 1.2	61.3 ± 1.2	62.9 ± 1.3^a^,^c	62.7 ± 1.3^a
PTV in OAR	54.4 ± 1.8	56.4 ± 2.4	58.7 ± 2.9^a	57.3 ± 2.1^c
C. lung	0.5 ± 0.2	0.5 ± 0.2	0.5 ± 0.1	0.5 ± 0.1
Total lung – PTV	2.1 ± 0.6	2.1 ± 0.6	2.0 ± 0.6	2.0 ± 0.6
Ring	28.8 ± 2.2	29.3 ± 2.1	27.9 ± 2.2^a	28.0 ± 2.0^a
Max dose (Gy)
PTV in OAR	58.5 ± 3.5	60.7 ± 4.0	64.8 ± 4.7^a^,^c	62.6 ± 3.7^a^,^b^,^c
Thoracic wall	51.1 ± 9.3	53.0 ± 11.1	54.1 ± 12.5	52.5 ± 11.4
Spinal cord	4.7 ± 4.4	4.8 ± 3.5	3.7 ± 1.0	4.5 ± 2.8
Esophagus	6.3 ± 2.4	6.4 ± 2.6	7.1 ± 2.8^a^,^c	7.1 ± 2.3^a
Trachea	4.0 ± 2.8	4.7 ± 3.1^c	5.8 ± 4.2^c	5.3 ± 3.5^c
Monitor units	6507 ± 1346	4653 ± 477^c	5037 ± 501^a^,^c	4895 ± 499^b,^c

C. lung: contralateral lung; V_X: volume receiving × Gy.

^a Indicates a statistically significant difference (p < 0.05) between Model_{3 × 18/COMBI} and Clinical(PO);

^b Indicates a statistically significant difference (p < 0.05) between Model_COMBI and Model_3 × 18;

^c Indicates a statistically significant difference (p < 0.05) between Clinical and Clinical(PO) or Model_{3 × 18/COMBI}.